drugset
drugset / Trial / NCT05012423

FTIH Study of ECC0509 in Healthy Volunteers

NCT05012423 ↗

Phase 1 Completed 89 enrolled Eccogene
RandomizedSequentialTriple-blindTreatment

Summary

A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single And Multiple Ascending Dose, First-Time-In-Human Study to Assess The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ECC0509 in Healthy Volunteers.

Timeline

Start
2021-07-26
Primary completion
2023-07-22
Completion
2023-07-22

Drugs

EvaluationDrugModalityDoseRoute
Subject ECC0509 Unknown 1 mg Oral
Subject ECC0509 Unknown 3 mg Oral
Subject ECC0509 Unknown 4 mg Oral
Subject ECC0509 Unknown 10 mg Oral
Subject ECC0509 Unknown 20 mg Oral
Subject ECC0509 Unknown 30 mg Oral
Subject ECC0509 Unknown 40 mg Oral
Subject ECC0509 Unknown 60 mg Oral
Subject ECC0509 Unknown 80 mg Oral

Indications

metabolic dysfunction-associated steatohepatitis osteoarthritis